We greatly appreciate our honoured partners of the Trade Mission: Navigating Asia for thier collaboration
ありがとうございました | Thank you | 고맙습니다
UK BioIndustry Association
Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative life sciences in the UK. Their goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling thier world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. Find more at www.bioindustry.org
Cell & Gene Therapy Catapult
The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 120 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. For more information please visit ct.catapult.org.uk
CJ PARTNERS Inc. offers management consulting and M&A advisory services by “made in Japan” Americans. Our mission is to bring the assets of a unique bicultural experience to serve Japan’s economy and society. For more info, visit www.cj-partners.com/en
Korea Drug Research Association (KDRA)
From its establishment KDRA has been working for the development of Korean Pharmaceutical & Biotech industries promoting the industrial technologies in pharmaceutical & biotech fields. For this KDRA has been participating in and leading biotech R&D policy-making, strategy formulating and improvement of advanced R&D systems. KDRA has since 1986 engaged in mid-and long-term nat'l R&D programs, drived and managed various kinds of R&D programs including those sponcered by the government in several innovation areas; NCE, NME, API, herbal medicine, New Indication, New Route of Administration, New Formulation, New Ester, Salt or Other Non-covalent Derivative, New Dosage Form or Strength, Combination Product etc. Find out more at www.kdra.or.kr/english/01web03.php
LSK Global PS
LSK Global Pharma Services Co., Ltd. (LSK Global PS) is a leading Contract Research Organization (CRO) in Korea and is making its endless effort to contribute to the expansion of Korean pharmaceutical industry into the global market.
Since March 2000, when LSK Global PS kicked off its business, LSK Global PS has established its position as a one-stop, full-service CRO encompassing all of the major areas of clinical research, i.e. registration trials from phase I to III, investigator-sponsored clinical studies, post-registration studies such as phase IV studies, PMS studies, observational studies, etc., and consulting services for new drug development. As of December 2017, we have conducted about 982 clinical studies so far, including about 560 registration trials and about 115 global clinical studies. Find out more at www.lskglobal.com/eng
MaSTherCell S.A. is a dynamic and global Contract Development and Manufacturing Organization (CDMO) on a mssion to deliver optimized process industrialization capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market. The company is the subsidiary of Orgenesis Inc.. The heart of MaSTherCell is a team of highly dedicated experts combining strong experience in cGMP cell therapy manufacturing with a technology-focused approach and a substantial knowledge of the industry. From technology selection to business modeling, GMP manufacturing, process development, quality management and assay development, MaSTherCell’s teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. For more information, please visit www.masthercell.com.
International Society for Cellular Therapy (ISCT)
ISCT is a global society of clinicians, regulators, technologists, and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients' lives.
Akron Biotech is an innovative biotechnology company with a strategic focus on supplying GMP-qualified raw materials and services to the regenerative medicine industry. Akron manufactures a range of products for cell therapy discovery, development, and commercialization. These products include growth factors, sera and purified proteins, custom-made cell culture media, tailored scaffolds with biomaterials, and proprietary cryopreservation formulations. In addition, our Services and Capabilities such as raw materials qualification, logistics and packaging optimization, bioassay design, validation and regulatory services are one of the many opportunities for Akron to provide our customers unique knowledge and expertise. As an ISO-compliant company, Akron supports clients with rigorous documentation and quality standards to fulfill their regulatory demands. Our unique capabilities allow us to seamlessly transition from R&D to pre-clinical and clinical development with minimal change control and thus drive the emerging regenerative medicine sector to unmet clinical needs through affordable and seamless manufacturing options.
Anemocyte is a Biotech Manufacturing Organization (BMO); a biotech company active in the field of Cell and Gene Therapies (CGTs) that addresses CGT needs pro-actively offering one stop shop solutions and fostering exciting innovations.
- 14 years of GMP manufacturing of CGTs and biological drugs;
- 61 years of Contract Manufacturing within our Group (Holding F.I.S.)
- Process development and GMP capabilities (Somatic Cells, Non-Viral Modified Cells)
- High-Quality Plasmid for Viral Vector Manufacturing.
- Project 2020: to address up to commercial scale needs for CGTs Including manufacturing of Viral Vectors.
- Big Data Analysis.
B-MoGen provides cutting edge tools for gene delivery and gene editing which provide unique and powerful solutions to basic and applied research problems. Their founders have developed and licensed innovative new methods that use transposons and targeted nucleases to study human diseases and genetics in ways that are otherwise impossible. Providing tools and custom services, B-MoGen can accelerate your research and achieve what others cannot: targeting your favorite gene in your favorite cell.
CellGenix is a premium supplier of high-quality reagents and tools for cell therapy and regenerative medicine applications. As the first company to obtain a GMP manufacturing authorization for cell processing in Europe, we have more than 20 years of expertise in GMP manufacturing and development of cell therapy products.
We offer a comprehensive product portfolio in combination with expert regulatory and technical support to ensure a seamless transition from research to commercialization.
Our products combine a maximum of quality and safety with excellent performance due to the state-of-the-art production, stringent in-house quality control and comprehensive documentation.
Cook Regentec creates enabling technologies and tools for cell-based therapies and cGMP bioprocessing. From concept to commercialization, our product lines cover expansion, packaging, storing, thawing, delivering, and processing.
Fresenius Kabi (www.fresenius-kabi.us/lovo) is a leading global health care company that focuses on pharmaceuticals and medical devices used to care for critically and chronically ill patients. Through our recent acquisition of Fenwal, we bring over 60 years experience in cell collection, separation processing. Today, the team is focused on serving the needs of the Therapeutic Apheresis and Cellular Therapy communities. The gentle science design of the Fenwal Amicus platform brings precision MNC collection and therapeutic plasma exchange (TPE) to customers. Recently launched, Lovo is the only cell processing system that washes and concentrates white blood cells using filtration technology.
Invetech provides tailored manufacturing automation to the global cell and advanced therapy market. Invetech works with clients to translate clinical processes into commercially successful products, from stepwise platforms to turnkey automation. Robust therapy production systems are configured to client processes using a combination of off-the-shelf solutions, proprietary technology platforms and custom in-house engineering. Invetech and client teams work collaboratively to meet commercial, quality and therapeutic objectives. Invetech has over 15 years’ experience developing automated closed processing for regenerative medicine products, with over 50 projects delivered worldwide, and powered by almost 300 technical personnel across Melbourne, San Diego and Boston sites.